

Correction: *High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC*

Frigola J, Carbonell C, Iranzo P, *et al.* High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. *J ImmunoTher Cancer* 2022;**10**:e004197. doi: 10.1136/jitc-2021-004197

This article has been corrected since it was first published online. Author name 'Patricia Irazno' has been corrected to 'Patricia Iranzo'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;**10**:e004197corr1. doi:10.1136/jitc-2021-004197corr1

